Optimizing antiretroviral therapy in adolescents with perinatally acquired HIV-1 infection

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 12, 2010, Pages 1403-1416

  Foster, Caroline ^a   Fidler, Sarah ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

adherence; adolescents; antiretroviral therapy; bone toxicity; cardiovascular risk; neurocognitive function; perinatally acquired HIV; toxicity

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; INTEGRASE INHIBITOR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TIPRANAVIR; VITAMIN D; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BONE DENSITY; BONE DISEASE; BONE MINERALIZATION; BRAIN TOXICITY; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE REACTION; KIDNEY DISEASE; LIPOATROPHY; LONG TERM EXPOSURE; METABOLIC DISORDER; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PERINATAL INFECTION; REPRODUCTIVE HEALTH; REVIEW; RISK FACTOR; SIDE EFFECT; TABLET; VERTICAL TRANSMISSION; VIRUS LOAD; VITAMIN SUPPLEMENTATION;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; PARTURITION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VIRAL LOAD; YOUNG ADULT;

EID: 78650226212     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.129     Document Type: Review

References (126)

1. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dab is F; Ghent International AIDS Society (IAS) Working Group On HIV Infection In Women And Children. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 364(9441), 1236-1243 (2004).
2. Marston M, Zaba B, Salomon JA, Brahmbhatt H, Bagenda D. Estimating the net effect of HIV on child mortality in African populations affected by generalized HIV epidemics. J. Acquir. Immune Defc. Syndr. 38(2), 219-227 (2005).
3. Ferrand RA, Corbett EL, Wood R et al. AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic. AIDS 23 (15) , 2039-2046 (2009).
4. Grey GE. Adolescent HIV - cause for concern in Southern Africa. PLoS Med. 7(2), e1000227 (2010).
5. Ferrand R, Bandason T, Musvaire, P et al. Causes of acute hospitalization in adolescence: burden and spectrum of HIV-related morbidity in a country with an early-onset and severe HIV epidemic. PLoS Med. 7(2), e1000178 (2010).
6. Brady MT, Oleske JM, Williams PL et al. Declines in mortality rates and changes in causes of death in HIV-1 infected children during the HAART era. J. Acquir. Immune Defc. Syndr. 53(1), 86-94 (2010).
7. Judd A, Doerholt K, Tookey PA et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin. Infect. Dis. 45(7), 918-924 (2007).
8. Foster C, Judd A, Tookey P et al. Young people in the United Kingdom and Ireland with perinatally acquired HIV: the pediatric legacy for adult services. AIDS Patient Care STDS 23(3), 159-166 (2009).
9. Kekitiinwa A, Lee KJ, Walker AS et al. Collaborative HIV Paediatric Study (CHIPS) Steering Committe; Mulago Cohort Team. Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland. J. Acquir. Immune Defc. Syndr. 49(4), 384-392 (2008).
10. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group. Response to combination antiretroviral therapy: variation by age. AIDS 22(12), 1463-1473 (2008).
11. Shearer W T, Quinn TC, LaRussa P et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N. Engl. J. Med. 336(19), 1337-1342 (1997).
12. Menson EN, Walker AS, Sharland M. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study. Br. Med. J. 332(7551), 1183-1187 (2006).
13. Butler K; on behalf of PLATO 11 Project part of COHERE. Triple class virological failure in HIV-infected children. Arch. Intern. Med. 170(5), 410-419 (2010).
14. Gazzard BG, Anderson J, Babiker A, BHIVA Treatment Guidelines Writing Group. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 9(8), 563-608 (2008).
15. Welch S, Sharland M, Lyall EG et al.; PENTA Steering Committee. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med. 10(10), 591-613 (2009).
16. Thompson MA, Aberg JA, Cahn P et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304(3), 321-333 (2010).
17. Vignoles M, Barboni G, Agosti MR et al. High frequency of primary mutations associated with antiretroviral drug resistance in recently diagnosed HIV-infected children. Antivir. Ther. 12(7), 1133-1137 (2007).
18. Viani RM, Peralta L, Aldrovandi G et al. Adolescent Medicine Trials Network for HIV/AIDS Interventions. Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study. J. Infect. Dis. 194(11), 1505-1509 (2006).
19. Adams J, Patel N, Mankaryous N, Tadros M, Miller CD. Non-nucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents. Ann. Pharmacother. 44(1), 157-165 (2009).
20. UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group. Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. Clin. Infect. Dis. 50(9), 1275-1285 (2010).
21. Melvin A; PENPACT 1 Study Team. PENPACT-1 (PENTA 9/PACTG 390): a randomised trial of protease inhibitor (PI) vs non-nucleoside reverse transcriptase inhibitor (NNRTI) combination antiretroviral (ART) regimens and viral load (VL) treatment switching strategies in HIV-1-infected ART-naive children age >30 days and <18 years. Presented at: XVIII International AIDS Conference. Vienna, Austria, 18-23 July 2010 (Abstract THLBB104).
22. Lemburg DA, Palasanthiran P, Goode M, Zeigler JB. Tolerabilities of antiretrovirals in paediatric HIV infection. Drug Saf. 25(14), 973-991 (2002).
23. Del Rosa C. HIV treatment as prevention. The jury's still out, but current data seem to support the theory that ART use reduces the likelihood of HIV transmission. AIDS Clin. Care 22(1), 3-4 (2010).
24. Cohen MS, Fidler S. HIV prevention 2010: where are we now and where are we going? Curr. Opin. HIV AIDS 5(4), 265-268 (2010).
25. Neely M, Kovacs A. Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir. Ther. Clin. Risk Manag 5(3), 595-615 (2009).
26. Salazar JC, Cahn P, Yogev R et al. PACTG 1051/BI Study Team. Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents. AIDS 22(14), 1789-1798 (2008).
27. McKeage K, Scott LJ. Darunavir: in treatment-experienced pediatric patients with HIV-1 infection. Paediatr. Drugs 12(2), 123-131 (2010).
28. Blanche S, Bologna R, Cahn P et al. Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents. AIDS 23(15), 2005-2013 (2009).
29. Cahn P, Villacian J, Lazzarin A et al. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin. Infect. Dis. 43(10), 1347-1356 (2006).
30. Arastéh K, Yeni P, Pozniak A et al. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir. Ther. 14(6), 859-864 (2009).
31. Katlama C, Haubrich R, Lalezari J et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 23(17), 2289-2300 (2009).
32. Church JA, Hughes M, Chen J et al. Pediatric AIDS Clinical Trials Group P1005 Study Team. Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr. Infect. Dis. J. 23(8), 713-718 (2004).
33. Bellibas SE, Siddique Z, Dorr A et al. Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy. Pediatr. Infect. Dis. J. 23(12), 1137-1141 (2004). (Pubitemid 40812762)
34. Wiznia A, Church J, Emmanuel P et al. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients. Pediatr. Infect. Dis. J. 26(9), 799-805 (2007).
35. Palladino C, Briz V, González-Tomé MI et al. Short communication: evaluation of the effect of enfuvirtide in 11 HIV-1 vertically infected pediatric patients outside clinical trials. AIDS Res. Hum. Retroviruses 26(3), 301-305 (2010).
36. Viganò A, Meroni L, Marchetti G et al. Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1. Antivir. Ther. 13(6), 839-843 (2008).
37. Konigs C, Feiterna-Sperling C, Esposito S et al. Pharmacokinetics and dose selection of etravirine in HIV-infected children between 6 and 17 years, inclusive. Presented at: The 16th Conference on Reteroviruses and Opportunistic Infections (CROI). Montreal, Canada, 8-11 February 2009 (Abstract 879).
38. Puthanakit T, Jourdain G, Hongsiriwon S et al.; on behalf of the HIV-NAT 086 study team. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. HIV Med. 11(9), 565-572 (2010).
39. Thuret I, Chaix ML, Tamalet et al. Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistent virus. AIDS 23(17), 2366-2366 (2009).
40. Wiznia, A, Samson P, Acosta E et al. Safety and efficacy of raltegravir (RAL) in pediatric HIV infection: preliminary analysis from IMPAACT P1066. Presented at: The 16th Conference on Reteroviruses and Opportunistic Infections (CROI). Montreal, Canada, 8-11 February 2009 (Abstract 874).
41. Nachman S, Acosta E, Samson P et al. Interim Results from IMPAACT P1066: Raltegravir (RAL) Oral Chewable Tablet (OCT) Formulation in Children 6 to 11 Years. Presented at: The 17th Conference on Reteroviruses and Opportunistic Infections (CROI). San Francisco, CA, USA, 16-19 February 2010 (Abstract 161LB).
42. Gaur A, Abadi J, Wiznia A et al. Pharmacokinetics and safety of once-daily elvitegravir in HIV-infected adolescents. Presented at: The 17th Conference on Reteroviruses and Opportunistic Infections (CROI). San Francisco, CA, USA, 16-19 February 2010 (Abstract 874).
43. Church JD, Huang W, Mwatha A et al. HIV-1 tropism and survival in vertically infected Ugandan infants. J. Infect. Dis. 197(10), 1382-1388 (2008).
44. Lwembe R, Lihana RW, Ochieng W et al. Changes in the HIV type 1 envelope gene from non-subtype B HIV type 1-infected children in Kenya. AIDS Res. Hum. Retrovirus 25(2), 141-147 (2009).
45. El-Sadr WM, Lundgren JD, Neaton JD et al.; Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355(22), 2283-2296 (2006). (Pubitemid 44837777)
46. El-Sadr WM, Grund B, Neuhaus J et al.: SMART Study Group. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann. Intern. Med. 149(5), 289-299 (2008).
47. Burman WJ, Grund B, Roediger MP, Friedland G, Darbyshire J, Wu AW: SMART Study Group. The impact of episodic CD4 cell count-guided antiretroviral therapy on quality of life. J. Acquir. Immune Defc. Syndr. 47(2), 185-193 (2008).
48. Gibb DM, Compagnucci A, Green H et al. Treatment interruption in children with chronic HIV-infection: the results of the Paediatric European Network for Treatment of AIDS (PENTA) 11 trial. J. Inter. AIDS Soc. 11(Suppl. 1), 1-103 (2008).
49. Reynolds SJ, Kityo C, Hallahan C et al. A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda. PLoS ONE 5(4), e10307 (2010).
50. Cohen CJ, Colson AE, Sheble-Hall AG, McLaughlin KA, Morse GD. Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the fve-days-on, two-days-off (FOTO) study. HIV Clin. Trials 8(1), 19-23 (2007).
51. Rudy BJ, Sleasman J, Kapogiannis B et al. Adolescent Trials Network for HIV/AIDS Interventions. Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression. AIDS Res. Hum. Retroviruses. 25(6), 555-561 (2009).
52. Zajdenverg R, Podsadecki TJ, Badal-Faesen S et al. Similar safety and efficacy of once- and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks. J. Acquir. Immune Defc. Syndr. 54(2), 143-151 (2010).
53. LePrevost M, Green H, Flynn J et al. Pediatric European Network for the Treatment of AIDS 13 Study Group. Adherence and acceptability of once daily lamivudine and abacavir in human immunodeficiency virus type-1 infected children. Pediatr. Infect. Dis. J. 25(6), 533-537 (2006).
54. Maitland D, Jackson A, Osorio J, Mandalia S, Gazzard BG, Moyle GJ; Epivir-Ziagen (EZ) Switch Study Team. Switching from twice-daily abacavir and lamivudine to the once-daily fxed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy. HIV Med. 9(8), 667-672 (2008).
55. Mellins CA, Brackis-Cott E, Dolezal C, Abrams EJ. The role of psychosocial and family factors in adherence to antiretroviral treatment in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 23(11), 1035-1041 (2004).
56. Nachega JB, Hislop M, Nguyen H et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J. Acquir. Immune Defc. Syndr. 51(1), 65-71 (2009).
57. Ding H, Wilson C, Modjarrad K, McGwin G, Tang J, Vermund S. Predictors of suboptimal virologic response to highly active antiretroviral therapy among human immunodeficiency virus-infected adolescents: analyses of the reaching for excellence in adolescent care and health (REACH) project. Arch. Pediatr. Adolest. Med. 163(12), 1100-1105 (2009).
58. Sawyer SM, Drew S, Yeo MS, Britto MT Adolescents with a chronic condition: challenges living, challenges treating. Lancet 369(9571), 1481-1489 (2007).
59. Nakhla M, Daneman D, To T, Paradis G, Guttmann A. Transition to adult care for youths with diabetes mellitus: fndings from a Universal Health Care System. Pediatrics 124(6), 1134-1141 (2009).
60. Rudy BJ, Murphy DA, Harris DR, Muenz L, Ellen J. Adolescent Trials Network for HIV/AIDS Interventions. Prevalence and interactions of patient-related risks for nonadherence to antiretroviral therapy among perinatally infected youth in the United States. AIDS Patient Care STDS 24(2), 97-104 (2010).
61. Rudy BJ, Murphy DA, Harris DR, Muenz L, Ellen J; Adolescent Trials Network for HIV/AIDS Interventions. Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: a study of prevalence and interactions. AIDS Patient Care STDS 23(3), 185-194 (2009).
62. Lindsey JC, Bosch RJ, Rudy BJ, Flynn PM. Early patterns of adherence in adolescents initiating highly active antiretroviral therapy predict long-term adherence, virologic, and immunologic control. AIDS Patient Care STDS 23(10), 799-801 (2009).
63. Bundock H, Fidler S, Clarke S et al. Crossing the divide: transitional care services for young people with HIV - their views. AIDS Patient Care STDS (2010) (In Press).
64. Naar-King S, Parsons JT, Murphy D, Chen X, Harris D, Belzer ME. Improving health outcomes for youth living with the human immunodeficiency virus: a multisite randomized trial of a motivational intervention targeting multiple risk behaviours. Arch. Pediatr. Adolesc. Med. 163(12), 1092-1098 (2009).
65. Purdy JB, Freeman AF, Martin SC et al. Virologic response using directly observed therapy in adolescents with HIV: an adherence tool. J. Assoc. Nurses AIDS Care. 19(2), 158-165 (2002).
66. Weiner L, Mellins C, Marhefka S, Battles H. Disclosure of an HIV diagnosis to children: history, current research, and future directions. J. Dev. Behav. Pediatr. 28(2), 155-166 (2007).
67. Butler A, Williams P, Howland L et al. Impact of disclosure of HIV infection on health-related quality of life among children and adolescents with HIV infection. Paediatrics 123(3), 935-943 (2009).
68. Brogly SB, Watts DH, Ylitalo N et al. Reproductive health of adolescent girls perinatally infected with HIV. Am. J. Public Health 97(6), 1047-1052 (2007).
69. Williams B, Kenny J, Tookey P, Foster C; on behalf of HYPNet. Pregnancy outcomes in women growing up with HIV acquired perinatally or in early childhood.Presented at: British HIV Association 2010. Manchester, UK, 20-23 April 2010 (Abstract P144).
70. Soria A, Danise A, Galli L et al. Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trial. J. Clin. Virol. 47(3), 253-257 (2010).
71. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin. Infect. Dis. 50(10), 1387-1396 (2010).
72. Foster C, Melvin D, Biggs R, Malters S, Tudor Williams G, Lyall EGH. Neuro-developmental outcomes in children presenting aged less than 3 years of age with HIV-1 infection. Dev. Med. Child Neurol. 48(8), 677-682 (2006).
73. Coplan J, Contello KA, Cunningham CK et al. Early language development in children exposed to or infected with human immunodeficiency virus. Pediatrics 102, e8 (1998).
74. Smith R, Malee K, Leighty R et al. Women and Infants Transmission Study Group. Effects of perinatal HIV infection and associated risk factors on cognitive development among young children. Pediatrics 117(3), 851-862 (2006).
75. Wood SM, Shah SS, Steenhoff A P, Rutstein RM. The impact of AIDS diagnoses on long-term neurocognitive and psychiatric outcomes of surviving adolescents with perinatally acquired HIV. AIDS 23(14), 1859-1865 (2009).
76. Koekkoek S, de Sonneville LM, Wolfs TF, Licht R, Geelen SP. Neurocognitive function profle in HIV-infected school-age children. Eur. J. Paediatr. Neurol. 12(4), 290-297 (2008).
77. Garvey L, Paramesparan Y, Ashby J, Foster C, Fidler S, Winston A. High rates of asymptomatic neurocognitive impairment in vertically-acquired HIV-1 infected adolescents surviving to adulthood. J. AIDS (2010) (In Press).
78. Gadow KD, Chernoff M, Williams PL et al. Co-occuring psychiatric symptoms in children perinatally infected with HIV and peer comparison sample. J. Dev. Behav. Pediatr. 31(2), 116-128 (2010).
79. Mellins CA, Brackis-Cott E, Leu CS et al. Rates and types of psychiatric disorders in perinatally human immunodeficiency virus-infected youth and seroreverters. J. Child Psychol. Psychiatry 50, 1131-1138 (2009).
80. Murphy DA, Belzer M, Durako SJ, Sarr M, Wilson CM, Muenz LR; Adolescent Medicine HIV/AIDS Research Network. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus. Arch. Pediatr. Adolesc. Med. 159(8), 764-770 (2005).
81. Reisner SL, Mimiaga MJ, Skeer M, Perkovich B, Johnson CV, Safren SA. A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth. Top HIV Med. 17(1), 14-25 (2009).
82. Nugent NR, Brown LK, Belzer M, Harper GW, Nachman S, Naar-King S; Adolescent Trials Network for HIV/AIDS Interventions. Youth living with HIV and problem substance use: elevated distress is associated with nonadherence and sexual risk. J. Int. Assoc. Physicians AIDS Care 9(2), 113-115 (2009).
83. Arpadi SM, Horlick M, Thornton J, Cuff PA, Wang J, Kotler DP. Bone mineral content is lower in prepubertal HIV-infected children. J. Acquir. Immune Defc. Syndr. 29(5), 450-454 (2002).
84. Vigano A, Mora S. Adverse effects of antiretroviral therapy: focus on bone density. Expert Opin. Drug Safety 3(3), 199-208 (2004).
85. Castillo AB, Tarantal AF, Watnik MR, Martin RB. Tenofovir treatment at 30 mg kg/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta). J. Orthop. Res. 20(6), 1185-1189 (2002).
86. Grigsby I, Pham L, Mansky LM, Gopalakrishnan R, Mansky KC. Tenofovir-associated bone density loss. Ther. Clin. Risk Manag. 6, 41-47 (2010).
87. Gafni RI, Hazra R, Reynolds JC et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 118(3), 711-718 (2006).
88. Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J. Pediatr. 152(4), 582-584 (2008).
89. Mehta S, Giovannucci E, Mugusi FM et al. Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS ONE 5, e8770 (2010).
90. Mehta S, Hunter DJ, Mugusi FM et al. Perinatal outcomes, including mother-to-child transmission of HIV, and child mortality and their association with maternal vitamin D status in Tanzania. J. Infect.Dis. 200, 1022-1030 (2009).
91. Atkinson S, Bird L, Patel D, Monrose C, Tudor-Williams G, Foster C. Vitamin D deficiency in children with perinatally acquired HIV-1 infection living in the UK. Presented at: British HIV Association 2010. Manchester, UK, 20-23 April 2010 (Abstract P159).
92. McKinney RE Jr, Robertson JW. Effect of human immunodeficiency virus infection on the growth of young children. Duke Pediatric AIDS Clinical Trials Unit. J. Pediatr. 123, 579-582 (1993).
93. de Martino M, Tovo PA, Galli L et al. Italian register for HIV infection in children. puberty in perinatal HIV-1 infection: a multicentre longitudinal study of 212 children. AIDS 15(12), 1527-1534 (2001).
94. Isanaka S, Duggan C, Fawzi W W. Patterns of postnatal growth in HIV-infected and HIV-exposed children. Nutr. Rev. 67(6), 343-359 (2009).
95. Fakoya A, Lamba H, Mackie N et al. British HIV Association, BASHH and FSRH guidelines for the management of the sexual and reproductive health of people living with HIV infection 2008. HIV Med. 9(9), 681-720 (2008).
96. Renner RM, Edelman AB, Kaunitz AM. Depot medroxyprogesterone acetate contraceptive injections and skeletal health. Womens Health 6(3), 339-342 (2010).
97. Martínez E, Larrousse M, Gatell JM. Cardiovascular disease and HIV infection: host, virus, or drugs? Curr. Opin. Infect. Dis. 22(1), 28-34 (2009).
98. Lekakis J, Ikonomidis I. Cardiovascular complications of AIDS. Curr. Opin. Crit. Care 16(5), 408-412 (2010).
99. Currier J. Update on cardiovascular complications in HIV infection. Top HIV Med. 17(3), 98-103 (2009).
100. Boccara F. Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors. AIDS 22 (Suppl. 3), S19-S26 (2008).
101. Mulligan K, Harris DR, Monte D et al. Adolescent Trials Network 021 Protocol Team. Obesity and dyslipidemia in behaviorally HIV-infected young women. Clin. Infect. Dis. 50(1), 106-114 (2010).
102. Hazra R, Siberry GK, Mofenson LM. Growing up with HIV: children, adolescents and young adults with perinatally acquired HIV infection. Annu. Rev. Med. 61, 169-185 (2010)
103. Antiretroviral Therapy Cohort Collaboration. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int. J. Epidemiol. 38(6), 1624-1633 (2009).
104. Charakida M, Loukogeorgakis SP, Okorie MI et al. Increased arterial stiffness in HIV-infected children: risk factors and antiretroviral therapy. Antivir. Ther. 14(8), 1075-1079 (2009).
105. Bonnet D, Aggoun Y, Szezepanski I et al. Arterial stiffness and endothelial dysfunction in HIV-infected children. AIDS 18(7), 1037-1041 (2004).
106. Ross AC, Rizk N, O'Riordan MA et al. Relationship between infammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin. Infect. Dis. 49(7), 1119-1127 (2009).
107. Ross AC, O'Riordan MA, Storer N, Dogra V, McComsey GA. Heightened infammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children. Atherosclerosis 211(2), 492-498 (2010).
108. Pontrelli G, Martino AM, Tchidjou HK et al. HIV is associated with thrombophilia and high D-dimer in children and adolescents. AIDS 24(8), 1145-1151 (2010).
109. DAD Study Group: Friis-Møller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med. 356(17), 1723-1735 (2007).
110. Viganò A, Pattarino G, Cerini C, Zuccotti GV What happens to children growing up with HIV infection? It's time for a HAART to heart. Expert Rev. Anti Infect. Ther. 7(5), 495-498 (2009).
111. Giuliano Ide C, de Freitas SF, de Souza M, Caramelli B. Subclinical atherosclerosis and cardiovascular risk factors in HIV-infected children: PERI study. Coron. Artery Dis. 19(3), 167-172 (2008).
112. Alam N, Cortina-Borja M, Goetghebuer T et al. Risk factors for metabolic abnormality in a European cohort of HIV-infected children and adolescents. Presented at: XVIII International AIDS Conference. Vienna, Austria, 18-23 July 2010 (Abstract MOAB0404).
113. D:A:D Study Group; Sabin CA, Worm SW, Weber R et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371, 9622, 1417-1426 (2008).
114. Benson CRH, Zheng E, Smurzynski M et al. No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001 Presented at: The 16th Conference on Reteroviruses and Opportunistic Infections (CROI). Montreal, Canada, 8-11 February 2009 (Abstract 721).
115. Patel K, Mittleman MA, Colan SD, et al. Predictors of cardiac dysfunction among children and adolescents perinatally-infected with HIV-1. Presented at: XVIII International AIDS Conference. Vienna, Austria, 18-23 July 2010 (Abstract MOAB0405).
116. Chaparro AI, Mitchell CD, Abitbol CL et al. Proteinuria in children infected with the human immunodeficiency virus. J. Pediatr. 152(6), 844-849 (2008).
117. Ray PE. Taking a hard look at the pathogenesis of childhood HIV-associated nephropathy. Pediatr. Nephrol. 24(11), 2109-2119 (2009).
118. McCulloch MI, Ray PE. Kidney disease in HIV-positive children. Semin. Nephrol. 28(6), 585-594 (2008).
119. Andiman WA, Chernoff MC, Mitchell C et al. PACTG iDACS 617 Study Team. Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. Pediatr. Infect. Dis. J. 28(7), 619-625 (2009).
120. Viganò A, Zuccotti GV, Martelli L et al. Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study. Clin. Drug Investig. 27(8), 573-581 (2007).
121. Judd A, Boyd KL, Stöhr W et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS 24(4), 525-534 (2010).
122. Riordan A, Judd A, Boyd K et al. Collaborative HIV paediatric study. Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland. Pediatr. Infect. Dis. J. 28(3), 204-209 (2009).
123. Thorne C, Townsend CL, Peckham CS, Newell ML, Tookey PA. Pregnancies in young women with vertically acquired HIV infection in Europe. AIDS 21(18), 2552-2556 (2007).
124. Zorrilla C, Febo I, Ortiz I, Orengo JC, Miranda S. Pregnancy in perinatally HIV-infected adolescents and young adults, Puerto Rico, 2002. MMWR. Morb. Mortal. Wkly. Rep. 52, 149-151 (2003).
125. Chibber R, Khurranna A. Birth outcomes in perinatally HIV-infected adolescents and young adults in Manipur, India: Arch. Gynecol. Obstet. 271, 127-131 (2005).
126. Waters L, Gilling-Smith C, Boag F. HIV infection and subfertility. Int. J. STD AIDS 18(1), 1-6 (2007).